Since the beginning of November, two months up more than 10 times, with the new crown test reagents a fire nine Ann medical, became the 2021 to 2022 year-end and early years of the A-share market's most beautiful boy.
This morning, Nine Ann Medical announced that the U.S. subsidiary and the U.S. ACC signed a Purchase Contract on January 13, 2022, local time, to sell iHealth reagent kits products, the contract price and tax total amount of $ 1.275 billion (including shipping costs), or about 8.1 billion yuan, which is more than the company's 2020 annual audited revenue from the main business of the year 50%.
This is not the first order in the past two months. Just two days ago, Nine Healthcare announced that its U.S. subsidiary had received an order from the governments of New York and Massachusetts for new coronary antigen home self-testing reagents. Together with the new orders announced this morning, Nine Healthcare has accumulated $1.608 billion in contract orders.
Although the recent too demonic stock price trend, so that the nine Ann medical successively ate from the Securities and Exchange Commission fines and constantly prompted the risk of trading, but more and more from the U.S. new crown test reagent orders, or to the outside world to prove that the nine Ann medical crazy soaring market, is not without performance support, the demon of the demon stock demon to have a certain value. Only, this value is built on the right place, right time, right person.
Founded in 1995, nine Ann medical, the earliest main business is the production and sales of measuring blood pressure, blood sugar, heart rate and other household human health indicators instrument manufacturers. However, this business has been more competitive because of lower barriers. Under the attack of Johnson & Johnson, Roche and other international brands and domestic leaders such as Yuyue Medical and Sanuo Medical, the market share of Jiu'an Medical is not high.
In June 2010, nine Ann medical listed on the Shenzhen Stock Exchange, followed by three years, the share price is steady decline. But from 2013 to 2015 in just two years, nine Ann medical ushered in a wave of upsurge market, its share price soared 560%. The reason for this is to step on the outbreak of smart hardware and health awareness of the population to enhance the wind mouth.
At that time, Apple, Xiaomi, Huawei and other cell phone manufacturers, launched their own health smart wearable products, such as smart watches and smart bracelets. Aiming at this wind mouth of nine Ann medical, quickly to the mobile Internet transformation, and take advantage of the momentum to launch their own health wearable device brand iHealth. subsequently, nine Ann medical and Apple cooperation to launch the mobile Internet blood pressure meter, and then obtained millet 25 million U.S. dollars in venture capital investment, millet ecological chain.
The good news is that after 2015, the global growth rate of wearable device shipments fell off a cliff. Nine Ann Medical's stock price also went downhill quickly after the scenery.
Performance-wise, after 2013, Jiu'an Medical's revenue growth rate has been low. Until 2020 because of the outbreak of the epidemic, people for health awareness further enhancement as well as a long time home brought a larger demand outbreak.
Profitability, from 2013 to 2018, nine Ann medical net profit of the mother of three years is negative, the remaining three years is only about 0.1 billion yuan.
Health Intelligent hardware profits are thin, nine Ann medical transition Internet mobile intelligent hardware strategy did not meet the ideal expectations. However, it is not as good as God's plan, the new crown epidemic outbreak, nine Ann medical and quickly aim at the wind, cut into the new crown detection of this track. In particular, the rapid spread of the new mutant strain of Omicron globally has brought unprecedented opportunities to JiuAn Medical.
On November 8, NineAnn Medical announced that its iHealth home-use neocoronary antigen self-test reagent was approved by the US EUA announcement, and then the stock price surged in response.
After the Omicron outbreak, hospitalization and ICU rates in the U.S. due to neocoronavirus pneumonia have risen steeply. In the past week, the number of neocoronavirus pneumonia infections in the U.S. has skyrocketed by 70%, hospitalizations have increased by 33%, and deaths have risen by 40%. The rapid spread of omicron in the U.S. has created a huge demand for new crown pneumonia testing.
The fact that Jiuan was able to target this windfall and quickly get approval from the U.S. EUA is related to its years of deep cultivation of overseas markets. Early years, through the brand iHealth into the U.S. market Jiuan medical, whether in the medical production qualification license, or in the marketing channel, compared with other domestic new crown reagent testing manufacturers, have no small advantage.
From the nine Ann Medical regional revenue composition can be seen, starting in 2019, the company's foreign sales revenue then accounted for 64.5% of total revenue, more than half of the company's total revenue. And by 2020, the proportion of overseas sales revenue to total revenue is already as high as 80%.
In addition to the Omicron epidemic came to help nine Ann medical order performance, the domestic end of the year A shares too polarized market, but also led to the company's stock price continued to soar. Pharmaceuticals, consumer plates sharply retreated after a lack of rebound, new energy lithium plates began to flame out plunge, the lack of main line of the various funds, opened a crazy speculation demon stock market.
The recent nine Ann medical so stimulating market, so many shareholders heart. Sold early chest thumping, still holding the jittery, not entered the thought of whether they can still rush in to make a fortune. But in fact, all people have a **** knowledge in mind: Omicron epidemic sooner or later there is a day to subside, the new crown test is a basket of trading, nine Ann medical crazy soaring market and can not last.
As of now, the new crown test reagent company approved by the U.S. EUA is not the only one. The antigen self-testing reagents produced by Dongfang Bio and Aikang Bio have also been approved by the EUA, and the same can enter the U.S. market. Other medical biology companies such as Meikang Bio and Boto Bio are also rapidly developing and producing new crown detection reagent products and applying for FDA approval in the US.
Nine Ann Medical stock price soared at the same time, the company's management issued equity incentives have also been criticized by the outside world. In this incentive plan, the company intends to grant 7,385,000 stock options to incentive recipients, with an exercise price of 6.49 yuan / share. At the same time, the company for this equity incentive, repurchase 13.62 million shares, repurchase share price at 5.9 yuan / share to 7.64 yuan / share.
The appraisal requires that from 2021 to 2024, the company's revenue growth rate should not be less than 20%, 40%, 70% and 80% respectively.
It is worth noting that the appraisal requirement of this equity incentive is based on 2019. As we all know, in 2020, due to the outbreak of the epidemic, the performance of Jiu'an Medical has grown significantly. Now, the company's equity incentive measures to 2019 low performance as a base, can not help but attract people's imagination: the company is conveying benefits to the relevant personnel.
At the moment, nine Ann Medical's share price has soared to 75.28 yuan / share, and the company's performance last year exploded, has completed last year's target.
Silent for many years, an outbreak, nine Ann medical ate all the time and place and people and the dividends. This kind of market, difficult to meet for many years. But carefully dialed nine Ann medical recent in the A-share market glossy appearance, which is still an epidemic in the main business before the loss of many years of the company. Although its recent performance outbreak has a large number of orders to support, but with the epidemic gradually subsided, more and more competitors to enter the game to grab the cake, nine Ann Medical is like instantaneous fireworks, after the splendor, will fall rapidly. Drumming the game of passing the flowers, who all understand, but who do not want to believe that they are the last one to receive the flowers when the drum stops sounding.
This article was originally published in GlobeNewswire
.